Nuplazid (Pimavanserin Tartrate) Patent Expiration, LOE Window & CMS Spending

Nuplazid (Pimavanserin Tartrate) by Acadia Pharmaceuticals: FDA Orange Book core substance LOE 2030-10-29 (last listed 2037-09-23), 0 AB generics, $670.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcadia Pharmaceuticals
FDA Application & PathwayN207318 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-10-29
Last Listed Patent or Exclusivity Date2037-09-23
Orange Book Patents (*PED Extensions)9 patents (4 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$670.0M
2024 Medicare Part D Spend$657.8M
2024 Medicaid Spend$12.2M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 37.3% 2-yr change)